Join Now

Utah Life Sciences News & Events

Richard Hague

April 24, 2020

Richard Hague is an accomplished senior biotechnology executive with extensive commercial, operations, and general management experience who has worked with both private and public companies of various sizes. Currently, as Chief Operating Officer at PolarityTE, Richard oversees the day to day operations of a 150+ employee biotechnology business with two locations in Salt Lake City. Before joining PolarityTE, Richard was the Chief Commercial Officer at Anika Therapeutics, where he oversaw all global commercial activities, as well as the R&D and Clinical Research functions. Richard spent a significant portion of his career at Genzyme and later Sanofi (post Sanofi’s acquisition of Genzyme) where he held roles of increasing responsibility, culminating in his role as VP/General Manager of Sanofi’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard was involved in the launch of the first autologous cell therapy product that ultimately led to FDA’s establishment of the BLA regulatory pathway. Subsequently, he has led successful launches of innovative products in the biologics, small molecule and medical device markets.